Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Fundamental Analysis

USA - NASDAQ:XENE - CA98420N1050 - Common Stock

41.92 USD
-0.75 (-1.76%)
Last: 10/31/2025, 4:30:02 PM
41.92 USD
0 (0%)
After Hours: 10/31/2025, 4:30:02 PM
Fundamental Rating

3

Taking everything into account, XENE scores 3 out of 10 in our fundamental rating. XENE was compared to 534 industry peers in the Biotechnology industry. While XENE has a great health rating, there are worries on its profitability. XENE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XENE had negative earnings in the past year.
In the past year XENE has reported a negative cash flow from operations.
XENE had negative earnings in each of the past 5 years.
XENE had a negative operating cash flow in each of the past 5 years.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -41.26%, XENE perfoms like the industry average, outperforming 58.80% of the companies in the same industry.
XENE has a Return On Equity of -43.89%. This is in the better half of the industry: XENE outperforms 69.48% of its industry peers.
Industry RankSector Rank
ROA -41.26%
ROE -43.89%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XENE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, XENE has more shares outstanding
Compared to 5 years ago, XENE has more shares outstanding
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 46.09 indicates that XENE is not in any danger for bankruptcy at the moment.
The Altman-Z score of XENE (46.09) is better than 96.25% of its industry peers.
There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.09
ROIC/WACCN/A
WACCN/A
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 15.14 indicates that XENE has no problem at all paying its short term obligations.
XENE's Current ratio of 15.14 is amongst the best of the industry. XENE outperforms 90.82% of its industry peers.
XENE has a Quick Ratio of 15.14. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XENE (15.14) is better than 90.82% of its industry peers.
Industry RankSector Rank
Current Ratio 15.14
Quick Ratio 15.14
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for XENE have decreased strongly by -29.56% in the last year.
EPS 1Y (TTM)-29.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, XENE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.53% on average per year.
The Revenue is expected to grow by 376.77% on average over the next years. This is a very strong growth
EPS Next Y-43.44%
EPS Next 2Y-24.78%
EPS Next 3Y-15.34%
EPS Next 5Y13.53%
Revenue Next Year2459.98%
Revenue Next 2Y787.78%
Revenue Next 3Y594.4%
Revenue Next 5Y376.77%

3.3 Evolution

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XENE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XENE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as XENE's earnings are expected to decrease with -15.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.78%
EPS Next 3Y-15.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENON PHARMACEUTICALS INC

NASDAQ:XENE (10/31/2025, 4:30:02 PM)

After market: 41.92 0 (0%)

41.92

-0.75 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners109.33%
Inst Owner Change-0.52%
Ins Owners0.11%
Ins Owner Change0.84%
Market Cap3.23B
Revenue(TTM)7.50M
Net Income(TTM)-278228000
Analysts87.2
Price Target55.42 (32.2%)
Short Float %8.14%
Short Ratio8.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.46%
Min EPS beat(2)-5.82%
Max EPS beat(2)10.75%
EPS beat(4)3
Avg EPS beat(4)2.96%
Min EPS beat(4)-5.82%
Max EPS beat(4)10.75%
EPS beat(8)6
Avg EPS beat(8)5.02%
EPS beat(12)8
Avg EPS beat(12)2.99%
EPS beat(16)10
Avg EPS beat(16)1.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.41%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-5.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 430.99
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB 5.1
EV/EBITDA N/A
EPS(TTM)-3.55
EYN/A
EPS(NY)-4.7
Fwd EYN/A
FCF(TTM)-3.02
FCFYN/A
OCF(TTM)-3
OCFYN/A
SpS0.1
BVpS8.22
TBVpS8.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.26%
ROE -43.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.66%
Cap/Sales 20.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.14
Quick Ratio 15.14
Altman-Z 46.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)190.35%
Cap/Depr(5y)241.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
EPS Next Y-43.44%
EPS Next 2Y-24.78%
EPS Next 3Y-15.34%
EPS Next 5Y13.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2459.98%
Revenue Next 2Y787.78%
Revenue Next 3Y594.4%
Revenue Next 5Y376.77%
EBIT growth 1Y-33.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.7%
EBIT Next 3Y-5.47%
EBIT Next 5Y12.96%
FCF growth 1Y-69.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-76.98%
OCF growth 3YN/A
OCF growth 5YN/A

XENON PHARMACEUTICALS INC / XENE FAQ

What is the ChartMill fundamental rating of XENON PHARMACEUTICALS INC (XENE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to XENE.


What is the valuation status for XENE stock?

ChartMill assigns a valuation rating of 0 / 10 to XENON PHARMACEUTICALS INC (XENE). This can be considered as Overvalued.


What is the profitability of XENE stock?

XENON PHARMACEUTICALS INC (XENE) has a profitability rating of 1 / 10.


What is the expected EPS growth for XENON PHARMACEUTICALS INC (XENE) stock?

The Earnings per Share (EPS) of XENON PHARMACEUTICALS INC (XENE) is expected to decline by -43.44% in the next year.